Sign in to view content

Baseline Characteristics of Patients Who Did or Did Not Maintain 12-Week and 16-Week Aflibercept 8 mg Dosing Intervals in the Phase 2/3 PHOTON Trial

Eric W Schneider, MD

Video
Published 2023

Related

Six Monthly Intravitreal Aflibercept to Improve Macular Perfusion in Diabetic Retinopathy Without Macular Edema
Yoon Jeon Kim, MD
Annual Meeting Talks
2023
Real-World Evidence for Pneumatic Retinopexy in Patients With Primary Rhegmatogenous Retinal Detachment Meeting PIVOT Trial Criteria
Verena Juncal, MD
Annual Meeting Talks
2019
Qualitative and Quantitative Evaluation of Diabetic Choroidopathy Using Ultra-Widefield Indocyanine Green Angiography (UWF ICGA)
Young Hee Yoon, MD, PhD
Annual Meeting Talks
2021

Category: Diabetic Retinopathy

See more